NEURO-ONCOLOGY

NEURO-ONCOLOGY

NEURO-ONCOLOGY
影响因子:13.4
是否综述期刊:
是否预警:不在预警名单内
是否OA:
出版国家/地区:UNITED STATES
出版社:Oxford University Press
发刊时间:1999
发刊频率:Quarterly
收录数据库:SCIE/Scopus收录
ISSN:1522-8517

期刊介绍

Published monthly from January 2010, Neuro-Oncology is the official journal of the Society for Neuro-Oncology. Also affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology it is a truly global journal in the field.Dedicated to providing superior and rapid publication of information in all areas of neuro-oncology, the journal contains peer-reviewed articles and reviews, symposia on selected topics, published abstracts of annual meetings, and society news and announcements from around the world.
《神经肿瘤学》是神经肿瘤学会的官方期刊,自2010年1月起每月出版。该杂志还隶属于日本神经肿瘤学会和欧洲神经肿瘤学会,是该领域真正的全球性杂志。致力于提供神经肿瘤学所有领域的上级和快速信息出版,该杂志包括同行评审文章和评论,选定主题的研讨会,年度会议的出版摘要,以及来自世界各地的社会新闻和公告。
年发文量 204
国人发稿量 28.95
国人发文占比 0.14%
自引率 -
平均录取率0
平均审稿周期 一般,3-8周
版面费 -
偏重研究方向 医学-临床神经学
期刊官网 https://academic.oup.com/neuro-oncology
投稿链接 https://www.editorialmanager.com/N-O

期刊高被引文献

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz150
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noy091
Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noy145
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
来源期刊:Neuro-oncologyDOI:10.1093/NEUONC/NOZ124
Improved neuropsychological outcomes following proton therapy relative to x-ray therapy for pediatric brain tumor patients.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz070
An independently validated survival nomogram for lower grade glioma.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz191
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noz232
Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noy120
Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noy195
EANO Guideline on the Diagnosis and Treatment of Vestibular Schwannoma.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz153
Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz212
Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noy152
Introduction of novel agents in the treatment of primary CNS lymphoma.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noy193
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz119
Driver mutations in USP8 wild-type Cushing’s disease
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noz109
Sex-specific gene and pathway modeling of inherited glioma risk
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noy135
Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz031
Diet and risk of glioma: combined analysis of 3 large prospective studies in the UK and USA
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noz013
Sex difference of mutation clonality in diffuse glioma evolution
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noy154
Targeting Hypoxia Downstream Signaling Protein, CAIX, for CAR-T Cell Therapy against Glioblastoma.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz117
Molecular Profiling of Long-Term IDH-wildtype Glioblastoma Survivors.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz129
ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noy207
Prospective, longitudinal comparison of neurocognitive change in pediatric brain tumor patients treated with proton radiotherapy versus surgery only.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz041
The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz038
Deep-learning-based Detection and Segmentation-assisted Management on Brain Metastases.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz234
Proteomic analysis of meningiomas reveals clinically-distinct molecular patterns.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz084
Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines*
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noz034
Molecular correlates of cerebellar mutism syndrome in medulloblastoma.
来源期刊:Neuro-oncologyDOI:10.1093/NEUONC/NOZ158
Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET - Clinical relevance in glioma patients.
来源期刊:Neuro-oncologyDOI:10.1093/NEUONC/NOZ083
Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noy160
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz201
SECOND INTERIM AND FIRST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1P/19Q CODELETION
来源期刊:Neuro-oncologyDOI:10.1093/NEUONC/NOZ126.006
Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noy191
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz216
Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz090
Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz170
Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz155
Health status, Health-Related Quality of Life and Socio-economic Outcome in Childhood Brain Tumor Survivors: a German Cohort Study.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz044
Updates in the management of intradural spinal cord tumors: a radiation oncology focus.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz014
Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma
来源期刊:Neuro-OncologyDOI:10.1093/neuonc/noy105
Gene therapy with apoptosis-associated speck-like protein (ASC), a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz065
Cognitive and brain structural changes in long-term oligodendroglial tumor survivors.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz130
A low percentage of metastases in deep brain and temporal lobe structures.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz023
Differential Trajectories of Neurocognitive Functioning in Females versus Males Following Treatment for Pediatric Brain Tumors.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz092
Hippocampal sparing radiotherapy in adults with primary brain tumours: a comparative planning and dosimetric study using IMPT, IMRT and 3DCRT.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz167.008
Using surgical and oncology workload to plan brain tumour trial recruitment in England
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz167.047
To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs.
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz097
EXTH-28. TARGETED POLYGIONS ENGINEERED WITH SURFACE miRNAs FOR COMBINED MULTIMODALITY IMAGING AND ENHANCEMENT OF TEMOZOLOMIDE TREATMENT: A NOVEL INTRANASALLY-DELIVERED THERANOSTIC STRATEGY AGAINST GLIOBLASTOMA
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz175.360
Determination of meningioma brain tissue grades using Raman hyperspectral imaging
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz167.022
The Glioma Elephant in The Room
来源期刊:Neuro-oncologyDOI:10.1093/neuonc/noz167.072

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
73.53%39.4%0.88%-

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

查看说明
时间 预警情况
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
*来源:中科院《 国际期刊预警名单》

JCR分区

WOS分区等级:Q1区
版本 按学科 分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of Science)为每个学科内的期刊按照IF数值排 序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2024-2025年最新版)
CLINICAL NEUROLOGY
Q1

中科院分区

查看说明
版本 大类学科 小类学科 Top期刊 综述期刊
2025年3月最新升级版
医学1区
CLINICAL NEUROLOGY 临床神经病学
1区
ONCOLOGY 肿瘤学
1区
2023年12月升级版
医学1区
CLINICAL NEUROLOGY 临床神经病学
1区
ONCOLOGY 肿瘤学
1区
2022年12月旧的升级版
医学1区
CLINICAL NEUROLOGY 临床神经病学
1区
ONCOLOGY 肿瘤学
1区